Hyderabad-based Natco Pharma Ltd. has confirmed receipt of an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for its Finished Dosage Formulations (FDF) manufacturing facility located in Visakhapatnam, Andhra Pradesh.
The US FDA classified the inspection as Voluntary Action Indicated (VAI), a development disclosed by Natco Pharma in an exchange filing on November 20, 2026. The inspection of the Parawada unit in Visakhapatnam took place between August 17 and August 21, 2026. Following the inspection, the company had initially received four observations via Form 483.
Understanding the VAI Classification
A VAI classification from the US FDA signifies that while the agency identified certain conditions requiring attention, these do not warrant official regulatory action at this time. Instead, the FDA expects the company to voluntarily undertake corrective actions to address the identified issues. This classification is generally seen as less severe than Official Action Indicated (OAI).
Natco Pharma's latest communication confirms the formal receipt of the EIR and the VAI classification, referring back to its previous intimation regarding the August inspection.
Impact on Natco Pharma Stock
Shares of Natco Pharma were in focus following the announcement. The company's stock closed at Rs 821.50 on Thursday, reflecting a marginal increase of 0.13% from its previous close. During the trading session, the stock experienced fluctuations, opening at Rs 821.95 and touching a high of Rs 824.40.
The company submitted the details of the EIR and VAI classification under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to inform stock exchanges and investors.